Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort-Reference-Cited by-同舟云学术

Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort

Published:2016-10-28 Issue:1 Volume:131 Page:117-124
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Morris Katrina A.^ORCID, ,Golding John F.,Blesing Claire,Evans D. Gareth,Ferner Rosalie E.,Foweraker Karen,Halliday Dorothy,Jena Raj,McBain Catherine,McCabe Martin G.,Swampillai Angela,Warner Nicola,Wilson Shaun,Parry Allyson,Afridi Shazia K.

Funder

National Institute for Health Research

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Clinical Neurology,Neurology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11060-016-2276-9.pdf

Reference23 articles.

1. Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-Oncol 12(1):14–18. doi: 10.1093/neuonc/nop010

2. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358–367. doi: 10.1056/NEJMoa0902579

3. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG, 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neuro 33 (6):1046–1052. doi: 10.1097/MAO.0b013e31825e73f5

4. Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF (2014) The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Oto-Rhino-Laryngol. doi: 10.1007/s00405-014-3398-3

5. Hochart A, Gaillard V, Baroncini M, Andre N, Vannier JP, Vinchon M, Dubrulle F, Lejeune JP, Vincent C, Neve V, Sudour Bonnange H, Bonne NX, Leblond P (2015) Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neurooncol 124(2):229–236. doi: 10.1007/s11060-015-1828-8

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis;Journal of Clinical Oncology;2024-07-20

2. NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues;International Journal of Molecular Sciences;2024-06-14

3. Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience;Cancers;2024-04-12

4. Consensus guidelines for the management of vestibular schwannoma for low-and middle-income countries;J PAK MED ASSOC;2024

5. Fibroblasts Derived From Vestibular Schwannoma Express Protumorogenic Markers;Otology & Neurotology;2023-09-15